Back to Search Start Over

Sulfasalazine Resolves Joint Stiffness in a Rabbit Model of Arthrofibrosis

Authors :
Emily B Petersen
Sonja M. Smith
Douglas C. Fredericks
Marc J. Brouillette
Keerthi Atluri
James A. Martin
Dongrim Seol
Edward A. Sander
Timothy P. Fowler
Behnoush Khorsand
Aliasger K. Salem
Source :
Journal of orthopaedic research : official publication of the Orthopaedic Research SocietyREFERENCES. 38(3)
Publication Year :
2019

Abstract

Joint stiffness due to fibrosis/capsule contracture is a seriously disabling complication of articular injury that surgical interventions often fail to completely resolve. Fibrosis/contracture is associated with the abnormal persistence of myofibroblasts, which over-produce and contract collagen matrices. We hypothesized that intra-articular therapy with drugs targeting myofibroblast survival (sulfasalazine), or collagen production (β-aminopropionitrile and cis-hydroxyproline), would reduce joint stiffness in a rabbit model of fibrosis/contracture. Drugs were encapsulated in poly[lactic-co-glycolic] acid pellets and implanted in joints after fibrosis/contracture induction. Capsule α-smooth muscle actin (α-SMA) expression and intimal thickness were evaluated by immunohistochemistry and histomorphometry, respectively. Joint stiffness was quantified by flexion-extension testing. Drawer tests were employed to determine if the drugs induced cruciate ligament laxity. Joint capsule fibroblasts were tested in vitro for contractile activity and α-SMA expression. Stiffness in immobilized joints treated with blank pellets (control) was significantly higher than in non-immobilized, untreated joints (normal) (p = 0.0008), and higher than in immobilized joints treated with sulfasalazine (p = 0.0065). None of the drugs caused significant cruciate ligament laxity. Intimal thickness was significantly lower than control in the normal and sulfasalazine-treated groups (p = 0.010 and 0.025, respectively). Contractile activity in the cells from controls was significantly increased versus normal (p = 0.001). Sulfasalazine and β-aminopropionitrile significantly inhibited this effect (p = 0.005 and 0.0006, respectively). α-SMA expression was significantly higher in control versus normal (p = 0.0021) and versus sulfasalazine (p = 0.0007). These findings support the conclusion that sulfasalazine reduced stiffness by clearing myofibroblasts from fibrotic joints. Statement of clinical significance: The results provide proof-of-concept that established joint stiffness can be resolved non-surgically. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:629-638, 2020.

Details

ISSN :
1554527X
Volume :
38
Issue :
3
Database :
OpenAIRE
Journal :
Journal of orthopaedic research : official publication of the Orthopaedic Research SocietyREFERENCES
Accession number :
edsair.doi.dedup.....e6c802b193d1d4c73c6b0b2a15eec1ea